国际肿瘤学杂志

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (7): 536-540.doi: 10.3760/cma.j.issn.1673422X.2014.07.017

• 综述 • 上一篇    下一篇

芳香化酶抑制剂相关骨关节疼痛研究进展

 董欣悦, 方立萍, 蒋葵   

  1. 163000 大连医科大学研究生院第二临床学院（董欣悦）；大连医科大学附属第二医院肿瘤科（方立萍、蒋葵）
  • 出版日期:2014-08-04 发布日期:2014-08-04
  • 通讯作者: 蒋葵，Email:jk0411@163.com E-mail:jk0411@163.com

Research of aromatase inhibitorassociated arthralgia

 DONG  Xin-Yue, FANG  Li-Ping, JIANG  Kui   

  1. *Second Clinical College of Dalian Medical University Graduate School, Dalian 163000, China
  • Online:2014-08-04 Published:2014-08-04
  • Contact: Jiang Kui E-mail:jk0411@163.com

PDF

1498

摘要： 芳香化酶抑制剂（AI）是绝经后乳腺癌激素受体阳性患者内分泌治疗的主要药物，但其不良反应骨关节疼痛(AIA)潜在影响这类药物的临床实用。目前关于AIA的发生机制并不十分清楚，文献报道与雌激素水平下降、免疫指标异常、腱鞘变化及关节积液等有关。在临床中重视并选择适当手段治疗AIA，减少AIA的发生，有助于提高使用AI的依从性。

关键词: 疼痛, 乳腺肿瘤, 芳香化酶抑制剂

Abstract: Aromatase inhibitors (AI) are the leading care for the adjuvant treatment of hormone responsive carcinoma of the breast as  demonstrated in a number of large international phase III randomised trials. Aromatase inhibitorassociated arthralgia（AIA）was a somewhat unexpected side effect of this class of agents and has proven to be potentially problematic in clinical practice. The pathogenesis of AIA is not very clear currently, with the cause of most research focusing on estrogen deprivation，immune abnormalities，tenosynovial changes and joint effusions. It is extremely urgent that we evaluate this syndrome and select appropriate therapeutic strategies to reduce the incidence of AIA，thereby improving breast cancerrelated outcomes.

Key words: Pain, Breast neoplasms, Aromatase inhibitors